Checkpoint Therapeutics announced the long-term data obtained in its key study on the PD-L1 inhibitor cosibelimab for the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC).

Recently, a study has been published in The Lancet, which conducted a clinical trial comparing the efficacy and safety of the anti-PD-1 antibody camrelizumab combined with the VEGFR2-targeted TKI rivoceranib (also known as apatinib) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.

Yeast-like Candida albicans and Candida glabrata, as well as filamentous fungi from the Aspergillus genus, are primary causes of systemic fungal diseases for susceptible individuals. The emergence of multidrug-resistant Candida fungi, such as Candida auris, also presents a major global health challenge.

Betibeglogene autotemcel, also known as Lovotibeglogene autotemcel and marketed as ZYNTEGLO, is an intravenous injection developed by bluebird bio, Inc.

Biogen, Inc. is a pharmaceutical company that was founded in 1978 and is headquartered in Massachusetts, United States.

Dostarlimab gxly, trade name JEMPERLI, is a monoclonal antibody targeting PD-1, originally discovered by AnaptysBio, Inc., and signed a cooperation and exclusive license agreement with TESARO, Inc. (a GSK subsidiary) in March 2014.

Iptacopan, also known as LNP023, is the first oral small moleculecompletion factor B (CFB) inhibitor developed by Novartis Pharma AG.

The study proposes new strategies for predicting tumor immunotherapy efficacy based on multi-omics studies.

On July 26, 2023, Astellas and PeptiDream announced that they have entered into a research collaboration and licensing agreement to discover innovative protein degradation drugs for two targets selected by Astellas.

On July 26, 2023, Tarsus Pharmaceuticals announced that the U.S. FDA has approved Xdemvy (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis.

Empagliflozin is the first Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor to statistically significantly reduce the risk of hospitalization for any cause compared to a placebo in patients with CKD.

PRGN-2012 is a therapeutic vaccine that achieves therapeutic effects through immune stimulation.